Nilsson B, Sjölund K, Kindblom L-G, Meis-Kindblom J M, Bümming P, Nilsson O, Andersson J, Ahlman H
Lundberg Laboratory for Cancer Research, Department of Surgery at the Sahlgrenska Academy, Göteborg University, Göteborg 41345, Sweden.
Br J Cancer. 2007 Jun 4;96(11):1656-8. doi: 10.1038/sj.bjc.6603797. Epub 2007 May 29.
Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly in patients with tumours harbouring activating KIT mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a consecutive series of patients with high-risk tumours (n=23) was compared with historic controls (n=48) who were treated with surgery alone. The mean follow-up period was over 3 years in both groups. Only 1 out of 23 patients (4%) in the adjuvant treatment group developed recurrent disease compared to 32 out of 48 patients (67%) in the control group. This preliminary study indicates that 1 year of adjuvant treatment with imatinib dramatically improves recurrence-free survival. Confirmation of these findings awaits the results of ongoing randomised studies.
姑息性伊马替尼治疗显著提高了恶性胃肠道间质瘤患者的生存率，尤其是对于携带激活型KIT突变肿瘤的患者。为了评估根治性手术后辅助性伊马替尼的疗效，将连续纳入的一系列高危肿瘤患者（n = 23）与仅接受手术治疗的历史对照患者（n = 48）进行了比较。两组的平均随访期均超过3年。辅助治疗组的23例患者中只有1例（4%）出现疾病复发，而对照组的48例患者中有32例（67%）复发。这项初步研究表明，伊马替尼辅助治疗1年可显著提高无复发生存率。这些发现有待正在进行的随机研究结果予以证实。
